Changes in the epidemiological landscape of invasive candidiasis

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue , 2018, Pages i4-i13

  Lamoth, Frederic ^a,b   Lockhart, Shawn R ^c   Berkow, Elizabeth L ^c   Calandra, Thierry ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MORTALITY RATE; NEWBORN; NONHUMAN; ORGAN TRANSPLANTATION; RESEARCH; CANDIDA ALBICANS; CLINICAL RESEARCH; DISEASE SURVEILLANCE; ANTIMICROBIAL STEWARDSHIP; CLASSIFICATION; DRUG EFFECT; EPIDEMIOLOGICAL MONITORING; GLOBAL HEALTH; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVALENCE;

ANTIFUNGAL AGENTS; ANTIMICROBIAL STEWARDSHIP; CANDIDA; CANDIDIASIS, INVASIVE; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGICAL MONITORING; GLOBAL HEALTH; HUMANS; PREVALENCE;

EID: 85040160617     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx444     Document Type: Article

References (148)

1. Magill SS, Edwards JR, BambergWet al. Multistate point-prevalence survey of health care-associated infections. NEngl JMed2014; 370: 1198-208
2. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstreaminfections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17
3. Trick WE, Fridkin SK, Edwards JR et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30
4. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9
5. Nguyen MH,Wissel MC, Shields RK et al. Performance of Candida real-time polymerase chain reaction, b-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54: 1240-8
6. Fortun J, Meije Y, Buitrago MJ et al. Clinical validation of a multiplex realtime PCR assay for detection of invasive candidiasis in intensive care unit patients. J Antimicrob Chemother 2014; 69: 3134-41
7. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55: 1352-61
8. Cleveland AA, Harrison LH, Farley MM et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two USmetropolitan areas, 2008-2013: results from population-based surveillance. PLoS One 2015; 10: e0120452
9. Fagan RP, Edwards JR, Park BJ et al. Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990-2010. Infect Control Hosp Epidemiol 2013; 34: 893-9
10. Chapman B, Slavin M, Marriott D et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother 2017; 72: 1103-8
11. Hesstvedt L, Gaustad P, Andersen CT et al. Twenty-two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect 2015; 21: 938-45
12. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487-94
13. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J ClinMicrobiol 2011; 49: 325-34
14. Puig-Asensio M, Padilla B, Garnacho-Montero J et al. Epidemiology and predictive factors for early and latemortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2014; 20:O245-54
15. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: casecontrol population-based surveillance study of patients in Barcelona, Spain, from2002 to 2003. JClinMicrobiol 2006; 44: 1681
16. Oeser C, Lamagni T, Heath PT et al. The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009. Pediatr Infect Dis J 2013; 32: 23-6
17. Ulu Kilic A, Alp E, Cevahir F et al. Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country. Mycoses 2017; 60: 198-203
18. Kreusch A, Karstaedt AS. Candidemia among adults in Soweto, South Africa, 1990-2007. Int J Infect Dis 2013; 17: e621-3
19. Hii IM, Chang HL, Lin LC et al. Changing epidemiology of candidemia in a medical center in middle Taiwan. J Microbiol Immunol Infect 2015; 48: 306-15
20. Tan BH, Chakrabarti A, Li RY et al. Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect 2015; 21: 946-53
21. Hoffmann-Santos HD, Paula CR, Yamamoto AC et al. Six-year trend analysis of nosocomial candidemia and risk factors in twointensive care hospitals inMato Grosso,midwest region of Brazil. Mycopathologia 2013; 176: 409-15
22. Motta AL, AlmeidaGM, Almeida Junior JN et al. Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Braz J Infect Dis 2010; 14: 441-8
23. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. JClinMicrobiol 2006; 44: 2816-23
24. Santolaya ME, Alvarado T, Queiroz-Telles F et al. Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J 2014; 33: e40-4
25. Pfaller MA, Jones RN, Castanheira M. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 2014; 57: 602-11
26. Lockhart SR, Iqbal N, Cleveland AA et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U. S. cities from 2008 to 2011. JClinMicrobiol 2012; 50: 3435-42
27. Matsumoto E, Boyken L, Tendolkar S et al. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis 2014; 79: 205-8
28. Trouve C, Blot S, Hayette MP et al. Epidemiology and reporting of candidaemia in Belgium: a multi-centre study. Eur J Clin Microbiol Infect Dis 2017; 36: 649-55
29. Odds FC, Hanson MF, Davidson AD et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 1066-75
30. Doi AM, Pignatari AC, Edmond MB et al. Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian National Surveillance Program. PLoS One 2016; 11: e0146909
31. Nucci M, Queiroz-Telles F, Alvarado-Matute T et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013; 8: e59373
32. Pfaller MA, Moet GJ, Messer SA et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011; 49: 396-9
33. Govender NP, Patel J, Magobo RE et al. Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratorybased sentinel surveillance in SouthAfrica. J Antimicrob Chemother 2016; 71: 1994-2004
34. Tan TY, Hsu LY, Alejandria MM et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol 2016; 54: 471-7
35. Chakrabarti A, Sood P, Rudramurthy SM et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015; 41: 285-95
36. Farooqi JQ, Jabeen K, Saeed N et al. Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol 2013; 62: 259-68
37. van Hal SJ, Chen SC, Sorrell TC et al. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre(R) YeastOne(R) for Candida albicans: a prospective observational cohort study. J Antimicrob Chemother 2014; 69: 2210-4
38. Pfaller MA, Andes D, Diekema DJ et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilutionmethods. Drug Resist Updates 2010; 13: 180-95
39. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilutionmethods, 2010 to 2012. JClinMicrobiol 2012; 50: 2846-56
40. Orasch C, Marchetti O, Garbino J et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 2014; 20: 698-705
41. Shields RK, NguyenMH, Press EG et al. Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection. Antimicrob Agents Chemother 2015; 59: 7465-70
42. PfallerMA, Castanheira M, Lockhart SR et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-203
43. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-32
44. Pham CD, Iqbal N, Bolden CB et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58: 4690-6
45. SatohK, Makimura K, Hasumi Y et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53: 41-4
46. Chowdhary A, Sharma C, Duggal S et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 2013; 19: 1670-3
47. Magobo RE, Corcoran C, SeetharamS et al. Candida auris-associated candidemia, South Africa. Emerg Infect Dis 2014; 20: 1250-1
48. Calvo B, Melo AS, Perozo-Mena A et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect 2016; 73: 369-74
49. Lockhart SR, Etienne KA, Vallabhaneni S et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by wholegenome sequencing and epidemiological analyses. Clin Infect Dis 2017; 64: 134-40
50. Vallabhaneni S, Kallen A, Tsay S et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrugresistant fungus-United States,May 2013-August 2016. MMWR MorbMortal Wkly Rep 2016; 65: 1234-7
51. Schelenz S, Hagen F, Rhodes JL et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 2016; 5: 35
52. Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: 'newkid on the block' in hospital-associated infections? J Hosp Infect 2016; 94: 209-12
53. Chowdhary A, Anil Kumar V, Sharma C et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 2014; 33: 919-26
54. Colombo AL, Guimaraes T, Sukienik T et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. IntensiveCareMed2014; 40: 1489-98
55. Lortholary O, Renaudat C, Sitbon K et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive CareMed 2014; 40: 1303-12
56. Blumberg HM, JarvisWR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86
57. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-7
58. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patientswith Candida colonization. Crit CareMed 2006; 34: 730-7
59. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospectivemulticenter study. Crit CareMed 2009; 37: 1624-33
60. Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54: 46-51
61. Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-6
62. Playford EG, Lipman J, Jones M et al. Problematic dichotomization of risk for intensive care unit (ICU)-acquired invasive candidiasis: results using a risk-predictive model to categorize 3 levels of risk from a multicenter prospective cohort of Australian ICU patients. Clin Infect Dis 2016; 63: 1463-9
63. Wisplinghoff H, Ebbers J, Geurtz L et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents 2014; 43: 78-81
64. Li C, Wang H, Yin M et al. The differences in the epidemiology and predictors of death between candidemia acquired in intensive care units and other hospital settings. Intern Med 2015; 54: 3009-16
65. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: amulticenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8
66. Bassetti M, Righi E, Ansaldi F et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive CareMed 2015; 41: 1601-10
67. Lagunes L, Rey-Perez A, Martin-Gomez MT et al. Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain. Eur J Clin Microbiol Infect Dis 2017; 36: 95-104
68. Vergidis P, Clancy CJ, Shields RK et al. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS One 2016; 11: e0153247
69. Tissot F, Lamoth F, Hauser PM et al. b-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit CareMed 2013; 188: 1100-9
70. Bassetti M, Marchetti M, Chakrabarti A et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive CareMed 2013; 39: 2092-106
71. Leon C, Ruiz-Santana S, Saavedra P et al. Value of b-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive CareMed 2012; 38: 1315-25
72. Martin-Mazuelos E, Loza A, Castro C et al. b-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis. Intensive Care Med 2015; 41: 1424-32
73. Parra-Sanchez M, Zakariya-Yousef Breval I, Castro Mendez C et al. Candida albicans germ-tube antibody: evaluation of a new automatic assay for diagnosing invasive candidiasis in ICU patients. Mycopathologia 2017; 182: 645-52
74. Ostrosky-Zeichner L, Shoham S, Vazquez J et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 2014; 58: 1219-26
75. Timsit JF, Azoulay E, Schwebel C et al. Empirical micafungin treatment and survivalwithout invasive fungal infection in adultswith ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA 2016; 316: 1555-64
76. Calandra T, Bille J, Schneider R et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2: 1437-40
77. Dupont H, Paugam-Burtz C, Muller-Serieys C et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 2002; 137: 1341-6; discussion 7
78. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52
79. Sandven P, Qvist H, Skovlund E et al. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30: 541-7
80. Gamaletsou MN, Walsh TJ, Zaoutis T et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematologicalmalignancies. Clin Microbiol Infect 2014; 20: O50-7
81. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100
82. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75
83. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patientswith hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-52
84. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-73
85. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-70
86. Bergamasco MD, Garnica M, Colombo AL et al. Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil. Mycoses 2013; 56: 256-63
87. Puig-Asensio M, Ruiz-Camps I, Fernandez-Ruiz M et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clin Microbiol Infect 2015; 21: 491 e1-10
88. Bodey GP, MardaniM, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. AmJMed 2002; 112: 380-5
89. Hachem R, Hanna H, Kontoyiannis D et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9
90. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703
91. Schuster MG, Meibohm A, Lloyd L et al. Risk factors and outcomes of Candida krusei bloodstreaminfection: amatched, case-control study. J Infect 2013; 66: 278-84
92. Lockhart SR, Wagner D, Iqbal N et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol 2011; 49: 2404-10
93. Dufresne SF,Marr KA, Sydnor E et al. Epidemiology of Candida kefyr in patients with hematologicmalignancies. JClinMicrobiol 2014; 52: 1830-7
94. Slavin MA, Sorrell TC, Marriott D et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042-51
95. De Castro N, Mazoyer E, Porcher R et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007. Clin Microbiol Infect 2012; 18: E185-7
96. Kontoyiannis DP, Reddy BT, Torres HA et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34: 400-3
97. Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses 2012; 55: e74-84
98. Sallah S, Semelka RC, Wehbie R et al. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 1999; 106: 697-701
99. Marchetti O, Lamoth F, Mikulska M et al. ECIL recommendations for the use of biologicalmarkers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-54
100. Prella M, Bille J, Pugnale M et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005; 51: 95-101
101. Senn L, Robinson JO, Schmidt S et al. 1,3-β-D-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-85
102. Andes DR, Safdar N, Baddley JWet al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 2016; 18: 921-31
103. Neofytos D, Fishman JA, Horn D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220-9
104. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-11
105. Benjamin DK Jr, Stoll BJ, Fanaroff AA et al. Neonatal candidiasis among extremely low birthweight infants: risk factors,mortality rates, and neurodevelopmental outcomes at 18 to 22months. Pediatrics 2006; 117: 84-92
106. Benjamin DK Jr, Stoll BJ, Gantz MG et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126: e865-73
107. Fridkin SK, Kaufman D, Edwards JR et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004 Pediatrics 2006; 117: 1680-7
108. Lee JH, Hornik CP, Benjamin DK Jr et al. Risk factors for invasive candidiasis in infants. 1500 g birthweight. Pediatr Infect Dis J 2013; 32: 222-6
109. Xia H, Wu H, Xia S et al. Invasive candidiasis in preterm neonates in China: a retrospective study from 11 NICUs during 2009-2011. Pediatr Infect Dis J 2014; 33: 106-9
110. Aliaga S, Clark RH, Laughon M et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics 2014; 133: 236-42
111. Raymond J, Aujard Y; European Study Group. Nosocomial infections in pediatric patients: a European, multicenter prospective study. Infect Control Hosp Epidemiol 2000; 21: 260-3
112. Wisplinghoff H, Seifert H, Tallent SM et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22: 686-91
113. Mahieu LM, Van Gasse N,Wildemeersch D et al. Number of sites of perinatal Candida colonization and neutropenia are associated with nosocomial candidemia in the neonatal intensive care unit patient. Pediatr Crit Care Med 2010; 11: 240-5
114. Saiman L, Ludington E, PfallerMet al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-24
115. Steinbach WJ, Roilides E, Berman D et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J 2012; 31: 1252-7
116. Noyola DE, FernandezM,Moylett EH et al. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32: 1018-23
117. Rodriguez D, Almirante B, Park BJ et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006; 25: 224-9
118. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: E343-53
119. ZilberbergMD, Shorr AF, KollefMH. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008; 29: 978-80
120. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010; 14: e954-66
121. Pfaller M, Neofytos D, Diekema D et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-31
122. Oxman DA, Chow JK, Frendl G et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65: 1460-5
123. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10. 5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J ClinMicrobiol 2010; 48: 1366-77
124. Shields RK, NguyenMH, Clancy CJ. Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis 2015; 28: 514-22
125. Shields RK, Nguyen MH, Press EG et al. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013; 57: 3528-35
126. Kathuria S, Singh PK, Sharma C et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI BrothMicrodilution, and Etestmethod. J ClinMicrobiol 2015; 53: 1823-30
127. Zervou FN, Zacharioudakis IM, Kurpewski J et al. T2magnetic resonance for fungal diagnosis. MethodsMol Biol 2017; 1508: 305-19
128. Beyda ND, Alam MJ, Garey KW. Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagn Microbiol Infect Dis 2013; 77: 324-6
129. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60: 892-9
130. Bacconi A, Richmond GS, Baroldi MA et al. Improved sensitivity for molecular detection of bacterial and Candida infections in blood. J Clin Microbiol 2014; 52: 3164-74
131. Fernandez-Cruz A, Marin M, Kestler M et al. The value of combining blood culture and SeptiFast data for predicting complicated bloodstream infections caused by Gram-positive bacteria or Candida species. J ClinMicrobiol 2013; 51: 1130-6
132. Lamoth F, Jaton K, Prod'hom G et al. Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrileneutropenia. JClinMicrobiol 2010; 48: 3510-6
133. Metzgar D, Frinder MW, Rothman RE et al. The IRIDICA BAC BSI Assay: rapid, sensitive and culture-independent identification of bacteria and Candida in blood. PLoS One 2016; 11: e0158186
134. Bailly S, Maubon D, Fournier P et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.-trends over 10 years. J Infect 2016; 72: 103-11
135. Cornely OA, Bassetti M, Calandra T et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 Suppl 7: 19-37
136. HopeWW, Castagnola E, Groll AH et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention andmanagement of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18 Suppl 7: 38-52
137. Pappas PG, Kauffman CA, Andes DR et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: e1-50
138. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematologicalmalignancies and after haematopoietic stemcell transplantation (HCT). Clin Microbiol Infect 2012; 18 Suppl 7: 53-67
139. Lopez-Medrano F, San Juan R, Lizasoain M et al. A noncompulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013; 19: 56-61
140. Micallef C, Aliyu SH, Santos R et al. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. JAntimicrobChemother 2015; 70: 1908-11
141. Munoz P, Bouza E. The current treatment landscape: the need for antifungal stewardship programmes. J Antimicrob Chemother 2016; 71: ii5-12
142. Valerio M, Munoz P, Rodriguez CG et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect 2015; 21:492. e1-9
143. St-Germain G, Laverdiere M, Pelletier R et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008; 19: 55-62
144. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312
145. Asmundsdottir LR, Erlendsdottir H, GottfredssonM. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J ClinMicrobiol 2013; 51: 841-8
146. Bitar D, Lortholary O, Le Strat Y et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 20: 1149-55
147. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16
148. Rodriguez L, Bustamante B, Huaroto L et al. A multi-centric study of Candida bloodstreaminfection in Lima-Callao, Peru: species distribution, antifungal resistance and clinical outcomes. PLoS One 2017; 12: e0175172